Karmanos offers clinical trials for many different forms of cancer. Below are the most current clinical trials open to new participants as of this publication's issue date. If you have any questions regarding these clinical trials, please contact 313-576-9790.

To view the current issue online, please click here.

Get access to our clinical trials on your iPhone®, iPad® or Android™ mobile devices with the FREE KCI Trials App.

<table>
<thead>
<tr>
<th>Bone Marrow Transplant</th>
<th>Gynecologic</th>
<th>Immunotherapy</th>
<th>Phase 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Breast</td>
<td>Head &amp; Neck</td>
<td>Melanoma/Skin</td>
<td>Sarcoma</td>
</tr>
<tr>
<td>Gastrointestinal</td>
<td>Hematology</td>
<td>Neuro-Oncology</td>
<td>Thoracic</td>
</tr>
<tr>
<td>Genitourinary</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Bone Marrow Clinical Trials**

For more information on Bone Marrow Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

**BONE MARROW TRANSPLANT**

**STUDY 2015-115**  
Phase II  
A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL)

**STUDY 2014-103**  
Phase I/II  
A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

**STUDY BMTCTN1102**  
Phase III  
A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome.
STUDY 2016-109
Phase II
A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies (Protocol Number 15-MMUD).

STUDY NEW BMTCTN1506
Phase III
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteitinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML.

STUDY 2017-081
Phase III
Phase 3 Randomized Trial of Carfilzomib, Lenalidomide, Dexamethasone versus Lenalidomide Alone after Stem-Cell Transplant for Multiple Myeloma

STUDY 2016-209
Phase II
A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant

STUDY BMTCTN1302
Phase II
Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma.

STUDY 2017-072
Phase III
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Itacitinib or Placebo in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host Disease

STUDY A051301
Phase III
A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

STUDY 2011-203
Phase I/II
Phase I/II Study of Dasatinib in Recipients of Autologous Stem Cell Transplantation for Hematologic Malignancies.

STUDY 2016-194
Phase III
A Randomized, Double-Blind Phase 3 Study of Ibrutinib in Combination With Corticosteroids versus Placebo in Combination With Corticosteroids in Subjects with New Onset Chronic Graft Versus Host Disease (cGVHD)

STUDY 2016-049
Phase I/II
A Phase 1, Non-Randomized, Open-Label/Phase 2, Randomized, Blinded Study of ProTmune (ex vivo Programmed Mobilized Peripheral Blood Cells) Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects with Hematologic Malignancies

STUDY 2011-086
NA
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications.

RETURN TO TOP
<table>
<thead>
<tr>
<th>Study Code</th>
<th>Study Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADJUVANT</td>
<td></td>
</tr>
<tr>
<td>S1207</td>
<td>Phase III</td>
</tr>
<tr>
<td>Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer - e3 Breast Cancer Study - evaluating Everolimus with Endocrine Therapy.</td>
<td></td>
</tr>
<tr>
<td>B-55</td>
<td>Phase III</td>
</tr>
<tr>
<td>B-55/BIG 6-13: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy</td>
<td></td>
</tr>
<tr>
<td>A011202</td>
<td>Phase III</td>
</tr>
<tr>
<td>A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation In Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy</td>
<td></td>
</tr>
<tr>
<td>NRG-BR003</td>
<td>Phase III</td>
</tr>
<tr>
<td>A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer</td>
<td></td>
</tr>
<tr>
<td>A011502</td>
<td>Phase III</td>
</tr>
<tr>
<td>A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial</td>
<td></td>
</tr>
</tbody>
</table>

| NEOADJUVANT |
| STUDY 2015-137 | Phase I |
| A Phase 1b, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Trastuzumab Emtansine or with Trastuzumab and Pertuzumab (with and without Docetaxel) in Patients with HER2-Positive Breast Cancer and Atezolizumab with Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer |

| STUDY RT0G1304 | Phase III |
| NSABP B-51 RT0G1304: A Randomized Phase III Clinical Trial Evaluating Post Mastectomy Chest Wall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy. |

| STUDY EA1131 | Phase III |
| A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neo-adjuvant Chemotherapy |

| ADVANCED (STAGE IV) CHEMOTHERAPY |
| STUDY 2017-112 | Phase I/II |
| A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies |

| STUDY 2016-050 | Phase I |
| For more information on Breast Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for this clinical trial contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form. |
A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, an Anti-Glypican 3 (GPC3)/CD3 Bispecific Antibody, in Patients with Advanced Solid Tumors.

**STUDY 2017-064**  
**Phase I/II**  
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

**STUDY 2015-137**  
**Phase I**  
A Phase 1b, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Trastuzumab Emtansine or with Trastuzumab and Pertuzumab (with and without Docetaxel) in Patients with HER2-Positive Breast Cancer and Atezolizumab with Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer

**HORMONAL**  
**STUDY 2015-046**  
**Phase I**  
A Phase I, Multicenter, Open-Label, Two-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women with Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer

**STUDY 2016-034**  
**Phase I**  
A Phase 1b Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer

**STUDY 2015-137**  
**Phase I**  
A Phase 1b, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Trastuzumab Emtansine or with Trastuzumab and Pertuzumab (with and without Docetaxel) in Patients with HER2-Positive Breast Cancer and Atezolizumab with Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer

**OTHERS**  
**STUDY 2016-055**  
**Phase I**  
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

**STUDY 2016-116**  
**Phase II**  
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

**STUDY 2016-189**  
**Phase I**  
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study of SGN-2FF in Patients with Advanced Solid Tumors

**STUDY A011401**  
**Phase III**  
Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women With Early Breast Cancer

**STUDY 2017-029**  
**Phase I**  
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

**STUDY 2016-152**  
**Phase I**  
A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2017-018</td>
<td>I</td>
<td>A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women with Hormone Receptor Positive Breast Cancer</td>
</tr>
<tr>
<td>STUDY 2014-100</td>
<td>II</td>
<td>Cryoablation of Low Risk Breast Cancers less than 1.5 cm: An Evaluation of Local Recurrence (Ice3 Trial)</td>
</tr>
<tr>
<td>STUDY EAY131</td>
<td>II</td>
<td>Molecular Analysis for Therapy Choice (MATCH)</td>
</tr>
</tbody>
</table>

**Gastrointestinal Clinical Trials**

For more information on Gastrointestinal Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

**ESOPHAGUS**

**Metastatic**

**STUDY 2016-050**

Phase I

A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, an Anti-Glypican 3 (GPC3)/CD3 Bispecific Antibody, in Patients with Advanced Solid Tumors.

**STUDY 2017-064**

Phase I/II

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

**STUDY 2017-112**

Phase I/II

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

**GASTRIC AND GASTROESOPHAGEAL JUNCTION**

**Metastatic**

**STUDY 2016-210**

Phase I/II

An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

**STUDY NEW 2017-150**

Phase I/II

A Phase 1/2 Study of Olaparib in Combination with Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma

**STUDY 2017-064**

Phase I/II

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

**STUDY 2017-029**
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY 2017-112
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

STUDY 2017-054
Phase III
A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-Group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib plus Best Supportive Care (BSC) Compared to Placebo plus BSC in Patients with Advanced or Metastatic Gastric Cancer (GC)

STUDY 2017-087
Phase I
A Phase 1, Open-label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies

STUDY 2016-050
Phase I
A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, an Anti-Glypican 3 (GPC3)/CD3 Bispecific Antibody, in Patients with Advanced Solid Tumors.

STUDY 2015-156
Phase I
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

STUDY 2016-003
Phase I/II
A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

PANCREAS
Adenocarcinoma
Metastatic
STUDY 2017-050
Phase III
A Phase III Study of BBI-608 plus nab-Paclitaxel with Gemcitabine in Adult Patients with Metastatic Pancreatic Adenocarcinoma.

STUDY 2016-011
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination with nab-Paclitaxel Plus Gemcitabine Compared with Placebo Plus nab- Paclitaxel and Gemcitabine in Subjects with Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma

Neuroendocrine
STUDY EA2142
Phase II
Randomized Phase II Study of Platinum and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-Small Cell Gastroenteropancreatic Neuroendocrine Carcinomas

STUDY EA2161
Phase II
A Phase II Study of MLN0128 (TAK-228) in Rapalogs-Resistant Advanced Pancreatic Neuroendocrine Tumors (PNET)
<table>
<thead>
<tr>
<th>Study Number</th>
<th>Phase</th>
<th>Study Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2017-075</td>
<td>I</td>
<td>A Phase 1, First-in-Man, Multicenter, Open-Label, Dose-Escalation Study of Single-Agent GBR 1302 in Subjects with HER2 Positive Cancers</td>
</tr>
<tr>
<td>STUDY 2017-069</td>
<td>I/II</td>
<td>A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors</td>
</tr>
<tr>
<td>STUDY 2016-116</td>
<td>II</td>
<td>A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors</td>
</tr>
<tr>
<td>HCC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metastatic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY 2017-064</td>
<td>I/II</td>
<td>A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies</td>
</tr>
<tr>
<td>STUDY 2016-039</td>
<td>I/II</td>
<td>A Phase Ib/II Clinical Study of BBI608 in Combination with Sorafenib or BBI503 in Combination with Sorafenib in Adult Patients with Hepatocellular Carcinoma</td>
</tr>
<tr>
<td>STUDY 2017-112</td>
<td>I/II</td>
<td>A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies</td>
</tr>
<tr>
<td>STUDY 2016-079</td>
<td>I</td>
<td>An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma</td>
</tr>
<tr>
<td>BILIARY/GALL BLADDER</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Metastatic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY 2016-186</td>
<td>II</td>
<td>A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy</td>
</tr>
<tr>
<td>STUDY 2014-081</td>
<td>II</td>
<td>A Phase II Multicenter, Single Arm Study of Oral BGJ398 in Adult Patients with Advanced or Metastatic Cholangiocarcinoma with FGFR2 Gene Fusions or other FGFR Genetic Alterations who Failed or Are Intolerant to Platinum-Based Chemotherapy</td>
</tr>
<tr>
<td>COLON</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjuvant</td>
<td></td>
<td></td>
</tr>
<tr>
<td>STUDY A021502</td>
<td>III</td>
<td>Randomized Trial of Standard Chemotherapy Alone or Combined with Atezolizumab as Adjuvant Therapy of Patients with Stage III Colon Cancer with Deficient DNA Mismatch Repair</td>
</tr>
</tbody>
</table>
**Metastatic (Includes Rectal)**

**2nd Line**

**STUDY 2016-055**

**Phase I**

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

**STUDY 2017-112**

**Phase I/II**

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

**STUDY S1613**

**Phase II**

A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (MCRC) with HER-2 Amplification

**STUDY 2016-050**

**Phase I**

A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, an Anti-Glypican 3 (GPC3)/CD3 Bispecific Antibody, in Patients with Advanced Solid Tumors.

**STUDY 2016-157**

**Phase I**

Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

**STUDY 2016-185**

**Phase I/II**

A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer

**STUDY 2017-093**

**Phase I/II**

A Phase 2 Study of MEDI4736 (durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC

**STUDY 2016-003**

**Phase I/II**

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

**RECTUM**

**STUDY 2016-189**

**Phase I**

A Phase 1, Multicenter, Open-Label, Dose-Escalation Study of SGN-2FF in Patients with Advanced Solid Tumors

**OTHER**

**STUDY EAY131**

**Phase II**

Molecular Analysis for Therapy Choice (MATCH)

**STUDY 2017-064**

**Phase I/II**

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
## Genitourinary Clinical Trials

For more information on Genitourinary Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this [online referral form](#).

### RENAL

#### STUDY S1500

**Phase II**

A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

#### STUDY 2016-003

**Phase I/II**

A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors

#### STUDY 2016-037

**Phase I**

A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

#### STUDY 2017-037

**Phase II**

A Single-Arm, Open-Label, Multicenter, Extended Treatment, Safety Study in Patients Treated With Talazoparib

#### STUDY 2017-069

**Phase I/II**

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

#### STUDY 2017-112

**Phase I/II**

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

#### STUDY 2017-058

**Phase III**

A Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)

#### STUDY 2016-201

**Phase III**

A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects with Advanced Renal Cell Carcinoma (CLEAR).

#### STUDY 2017-111

**Phase I**

A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

#### STUDY 2017-083

**Phase II**

A Single-arm, Multicenter, Phase 2 Study to Evaluate Efficacy and Safety of Lenvatinib in Combination with Everolimus in Subjects with Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease

#### STUDY 2016-211

**Phase II**

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants with Advanced Renal Cell Carcinoma (FRACTION-RCC)
<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2016-126</td>
<td>Phase II</td>
<td>Phase II Study of Atezolizumab + Bevacizumab in Patients with Advanced Non-Clear Cell Renal Cell Carcinoma</td>
</tr>
<tr>
<td>STUDY 2016-050</td>
<td>Phase I</td>
<td>A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, an Anti-Glypican 3 (GPC3)/CD3 Bispecific Antibody, in Patients with Advanced Solid Tumors.</td>
</tr>
<tr>
<td>STUDY 2017-036</td>
<td>Phase I</td>
<td>A Phase I Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) in Patients With Advanced Solid Tumors and Normal or Varying Degrees of Renal Impairment</td>
</tr>
<tr>
<td>STUDY 2017-064</td>
<td>Phase I/II</td>
<td>A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies</td>
</tr>
<tr>
<td>STUDY 2017-029</td>
<td>Phase I</td>
<td>An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours</td>
</tr>
<tr>
<td>STUDY EA8143</td>
<td>Phase III</td>
<td>A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)</td>
</tr>
<tr>
<td>STUDY 2016-157</td>
<td>Phase I</td>
<td>Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2016-055</td>
<td>Phase I</td>
<td>A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers</td>
</tr>
<tr>
<td>STUDY 2009-139</td>
<td>Phase I</td>
<td>Phase I Safety, Pharmacokinetic and Pharmcodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer</td>
</tr>
<tr>
<td>STUDY 2014-010</td>
<td>Phase I</td>
<td>A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and other Malignant Solid Tumors that Express Nectin-4</td>
</tr>
<tr>
<td>STUDY 2015-156</td>
<td>Phase I</td>
<td>A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors</td>
</tr>
</tbody>
</table>

**Prostate**

<table>
<thead>
<tr>
<th>Study ID</th>
<th>Phase</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2013-108</td>
<td>NA</td>
<td>Immune Evaluation Study of Sipuleucel-T in African American and Non African American Men with Castrate Resistant Prostate Cancer</td>
</tr>
<tr>
<td>STUDY 2016-157</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY NRG-GU002
Phase II/III
Phase II-III Trial of Adjuvant Radiotherapy and Androgen Deprivation Following Radical Prostatectomy With or Without Adjuvant Docetaxel

STUDY 2017-047
Phase II
A Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone + Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

STUDY 2016-153
Phase I
A Phase 1 Safety and Tolerability Study of ZEN003694 in Combination with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer

STUDY 2017-065
Phase II
An Open-Label, Parallel, Phase II Study of Single-Agent Oral ESK981 in Men with Castrate-Resistant Prostate Cancer (CRPC)

STUDY RTOG0924
Phase III
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

STUDY 2016-069
Phase II
Phase II Trial of Pembrolizumab (MK-3475) in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated with Chemotherapy (KEYNOTE-199)

STUDY 2017-092
Phase II
A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy

STUDY 2015-167
Phase II
A Randomized Phase 2 Trial of Ascorbic Acid in Combination with Docetaxel in Men with Metastatic Prostate Cancer

STUDY NRG-GU003
Phase III
A Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)

STUDY 2017-051
Phase I
A Phase I Study of PCUR-101 in Combination with Androgen Suppression Therapy in the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer

STUDY 2017-046
Phase I
A Phase IB Open-Label, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK525762 in Combination with Androgen Deprivation Therapy and Other Agents in Subjects with Castrate Resistant Prostate Cancer (CRPC)

STUDY 2017-028
Phase I/II
A Phase I/II Trial of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Mifepristone for Patients with Metastatic Castration Resistant Prostate Cancer (CRPC)
STUDY 2015-029
Phase II
Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy

STUDY 2017-098
Phase III
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

STUDY 2015-057
Phase I
A Phase I, Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti-tumor Activity of AZD8186 in Patients with Advanced Castration-resistant Prostate Cancer (CRPC), Squamous Non-Small Cell Lung Cancer (sqNSCLC), Triple Negative Breast Cancer (TNBC) and Patients with Known PTEN-deficient/mutated or PIK3CB Mutated/amplified Advanced Solid Malignancies, as Monotherapy and in Combination with Abiraterone Acetate or AZD2014

BLADDER
STUDY 2016-055
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2016-050
Phase I
A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, an Anti-Glypican 3 (GPC3)/CD3 Bispecific Antibody, in Patients with Advanced Solid Tumors.

STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY 2017-070
Phase II
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in Patients with BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

STUDY 2015-084
Phase III
A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With, High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection

STUDY 2016-195
Phase II
Phase II Trial of Concurrent Nivolumab in UroThelial Bladder Cancer with Radiation Therapy in Localized/Locally Advanced Disease for Chemotherapy Ineligible Patients [NUTRA]

STUDY 2017-092
Phase II
A Single-arm, Open-label, Multicenter Study of Enfortumab Vedotin (ASG-22CE) for Treatment of Patients with Locally Advanced or Metastatic Urothelial Cancer who Previously Received Immune Checkpoint Inhibitor (CPI) Therapy

STUDY 2015-101
Phase I/II
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination with ALT-803 in patients with BCG-naïve Non-Muscle Invasive Bladder Cancer
<table>
<thead>
<tr>
<th>Study Code</th>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2016-003</td>
<td>Phase I/II</td>
<td>A Phase 1b/2 Study of Ibrutinib Combination Therapy in Selected Advanced Gastrointestinal And Genitourinary Tumors</td>
</tr>
<tr>
<td>STUDY 2017-075</td>
<td>Phase I</td>
<td>A Phase 1, First-in-Man, Multicenter, Open-Label, Dose-Escalation Study of Single-Agent GBR 1302 in Subjects with HER2 Positive Cancers</td>
</tr>
<tr>
<td>STUDY 2017-112</td>
<td>Phase I/II</td>
<td>A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies</td>
</tr>
<tr>
<td>STUDY 2017-064</td>
<td>Phase I/II</td>
<td>A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies</td>
</tr>
<tr>
<td>STUDY 2017-069</td>
<td>Phase I/II</td>
<td>A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors</td>
</tr>
<tr>
<td>STUDY 2016-175</td>
<td>Phase II</td>
<td>A Randomized Phase 2 Trial of Cisplatin/Gemcitabine with or without VX-970 in Metastatic Urothelial Carcinoma</td>
</tr>
<tr>
<td>STUDY 2016-157</td>
<td>Phase I</td>
<td>Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2014-010</td>
<td>Phase I</td>
<td>A Phase 1 Study of the Safety and Pharmacokinetics of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects with Metastatic Urothelial Cancer and other Malignant Solid Tumors that Express Nectin-4</td>
</tr>
<tr>
<td>STUDY 2015-072</td>
<td>Phase II</td>
<td>A Multicenter, Non-Randomized, Phase II Study of Regorafenib for Advanced Urothelial Cancer Following Prior Chemotherapy</td>
</tr>
<tr>
<td>OTHER</td>
<td>Study EAY131</td>
<td>Phase II</td>
</tr>
<tr>
<td>STUDY 2016-189</td>
<td>Phase I</td>
<td>A Phase 1, Multicenter, Open-Label, Dose-Escalation Study of SGN-2FF in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2017-076</td>
<td>Phase I/II</td>
<td>A Phase 1b/2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of B-701 Plus Docetaxel Versus Placebo Plus Docetaxel in the Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma in Subjects who have Relapsed After, or are Refractory to Standard Therapy</td>
</tr>
<tr>
<td>STUDY 2015-156</td>
<td>Phase I</td>
<td>A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced</td>
</tr>
</tbody>
</table>
Gynecologic Clinical Trials

For more information on Gynecologic Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

CERVIX
STUDY GOG-3009
Phase III
Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV

STUDY NRG-GY006
Phase II
Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

STUDY 2017-112
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

STUDY 2017-010
Phase II
A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2017-064
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

OVARY
STUDY 2017-064
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY 2017-153
Phase II
A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Niraparib Combined with Bevacizumab as Maintenance Treatment in Patients with Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Following
Front-Line Platinum-Based Chemotherapy with Bevacizumab

STUDY 2017-112
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

STUDY 2017-075
Phase I
A Phase 1, First-in-Man, Multicenter, Open-Label, Dose-Escalation Study of Single-Agent GBR 1302 in Subjects with HER2 Positive Cancers

STUDY 2017-105
Phase II
Phase 2 Study of VX-970 (NSC# 780162) in Combination with Gemcitabine versus Gemcitabine Alone in Subjects with Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer

STUDY 2017-085
Phase I
A Phase 1a/1b Dose Escalation and Expansion Study of Single-Agent SC-003 in Subjects with Platinum-Resistant/Refractory Ovarian Cancer

STUDY 2016-037
Phase I
A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

STUDY 2016-204
Phase II
Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy

STUDY GOG-3015
Phase III
A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab to Patients with Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

STUDY 2016-128
Phase III
ARIEL4 (Assessment of Rucaparib In Ovarian CancEr Trial): A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

UTERUS
STUDY GOG-0238
Phase II
A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus

STUDY 2017-064
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

VULVAR
STUDY GOG-0279
Phase II
A Phase II Trial Evaluating Cisplatin and Gemcitabine Concurrent with Intensity-Modulated Radiation Therapy (IMRT) for the Treatment of Locally-Advanced Squamous Cell Carcinoma of the Vulva
OTHER
STUDY NRG-GY006
Phase II
Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer

STUDY 2017-153
Phase II
A Phase 2, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Niraparib Combined with Bevacizumab as Maintenance Treatment in Patients with Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab

STUDY 2017-112
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

STUDY 2017-105
Phase II
Phase 2 Study of VX-970 (NSC# 780162) in Combination with Gemcitabine versus Gemcitabine Alone in Subjects with Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer

STUDY 2016-204
Phase II
Non-Randomized, Open-Label Phase II Study to Assess Olaparib Tablets as a Treatment for Subjects with Different HRD Tumor Status and with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer That Have Received at Least 2 Prior Lines of Chemotherapy

STUDY GOG-3015
Phase I/II
A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination with Paclitaxel, Carboplatin, and Bevacizumab to Patients with Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

STUDY EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)

RETURN TO TOP

Head & Neck Clinical Trials

For more information on Head & Neck Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

STAGES I/II/III
STUDY 2016-093
Phase I/II
A Phase 1b/2, Open-Label, Multicentre Study Assessing the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of MEDI4736 in Combination With AZD9150 or AZD5069 in Patients With Advanced Solid Malignancies and Subsequently Comparing AZD9150 and AZD5069 Both as Monotherapy and in Combination With MEDI4736 as Second Line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

STUDY EA3132
Phase II
Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing

**STUDY 2016-133**
**Phase II**
A Multicenter, Randomized, Double-Blind Phase 2 Trial of Lenvatinib (E7080) in Subjects With (131) I-Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 mg Daily Will Provide Comparable Efficacy to a 24-mg Starting Dose, But Have a Better Safety Profile

**STUDY 2017-042**
**Phase I/II**
A Phase 1b/2a, Multi-Center Open-Label Study to Evaluate the Safety and Efficacy of Combination Treatment with MEDI0457 (INO-3112) and Durvalumab (MEDI4736) in Patients with Recurrent/Metastatic Human Papilloma Virus Associated Head and Neck Squamous Cancer

**STUDY 2017-003**
**Phase III**
A Randomized Phase III Study of Pembrolizumab Given Concomitantly with Chemoradiation and as Maintenance Therapy versus Chemoradiation Alone in Subjects with Locally Advanced Head and Neck Squamous Cell Carcinoma

**STUDY 2016-165**
**Phase III**
A Randomized Double-Blind Phase 3 Study of Avelumab in Combination with Standard of Care Chemoradiotherapy (Cisplatin Plus Definitive Radiation Therapy) Versus Standard of Care Chemoradiotherapy in the Front-Line Treatment of Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck

**STAGES I - IV**
**STUDY 2016-050**
**Phase I**
A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, an Anti-Glypican 3 (GPC3)/CD3 Bispecific Antibody, in Patients with Advanced Solid Tumors.

**STUDY 2016-189**
**Phase I**
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study of SGN-2FF in Patients with Advanced Solid Tumors

**ANY STAGE**
**STUDY 2009-139**
**Phase I**
Phase I Safety, Pharmacokinetic and Pharmcodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

**STUDY 2016-212**
**Phase II**
A Phase 2 Study to Evaluate the Safety, Tolerability and Efficacy of Cell Transfer Therapy Using Autologous Tumor Infiltrating Lymphocytes (LN-145) followed by IL-2 in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

**STUDY 2017-107**
**Phase III**
A Pivotal, Double-Blind, Randomized, Placebo-Controlled, Multinational Study of SGX942(Dusquetide) for the Treatment of Oral Mucositis in Patients Being Treated with Concomitant Chemoradiation for the Treatment of Squamous Cell Carcinoma of the Head and Neck

**STUDY 2015-156**
**Phase I**
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2016-149
Phase I/II
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

STUDY 2016-017
Phase I/II
A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab* (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies

OTHER
STUDY EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)

STUDY 2017-112
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

STUDY 2016-055
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY 2017-087
Phase I
A Phase 1, Open-label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies

STUDY 2017-064
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2016-152
Phase I
A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors

Hematology Clinical Trials
For more information on Hematology Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

MULTIPLE MYELOMA
STUDY 2015-036
Phase II
A Phase II Study of IRD (Ixazomib, Lenalidomide, & Dexamethasone) for Consolidation Therapy Post Autologous Stem Cell Transplantation followed by Maintenance Ixazomib or Lenalidomide for Multiple Myeloma
STUDY 2012-122
Phase I/II
Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment with Pomalidomide, Dexamethasone, and Carfilzomib (PdC) in Subjects with Relapsed and Relapsed/Refractory Multiple Myeloma

STUDY 2016-119
Phase I
An Open-label, Dose-escalation and Multi-center Study to Evaluate the Safety, Pharmacokinetics and Efficacy of SAR650984 (Isatuximab) in Patients with Relapsed/Refractory Multiple Myeloma

STUDY 2016-120
Phase I
Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma

STUDY E1A11
Phase III
Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)

STUDY 2014-090
Phase I
A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor with Carfilzomib and Dexamethasone in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma.

STUDY 2015-022
Phase I
A Phase Ib Study of the Safety and Pharmacokinetics of Atezolizumab (ANTIPD-L1 ANTIBODY) Alone or in Combination with an Immunomodulatory Drug and/or Daratumumab in Patients with Multiple Myeloma (Relapsed and Post-Autologous Stem Cell Transplantation)

STUDY 2018-014
Phase I
A Phase I, Open-label Study to Evaluate the Safety, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MEDI2228 in Subjects with Relapsed/Refractory Multiple Myeloma

STUDY 2016-086
Phase I
A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination with Dexamethasone in Subjects with Relapsed and Refractory Multiple Myeloma

STUDY 2017-024
Phase II
A Single Arm, Open-Label, Phase 2 Study of Melflufen in Combination with Dexamethasone in Patients with Relapsed Refractory Multiple Myeloma who are Refractory to Pomalidomide and/or Daratumumab

AMYLOIDOSIS or LIGHT CHAIN DEPOSITION DISEASE
STUDY 2012-086
Phase III
A Phase 3, Randomized, Controlled, Open-Label, Multicenter, Safety and Efficacy Study of Dexamethasone Plus MLN9708 or Physicians Choice of Treatment Administered to Patients With Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

STUDY 2016-200
Phase II
A Randomized Phase 2 Trial of Revlimid/ Dexamethasone/ Elotuzumab +/- Cyclophosphamide followed by Revlimid/ Dexamethasone/Elotuzumab Maintenance as Second-line Therapy for Patients with Relapsed AL Amyloidosis

STUDY 2017-067
Phase III
Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis

STUDY 2016-060
Phase I
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Subjects with Relapsed or Refractory AML

LEUKEMIA
Acute Lymphoblastic Leukemia (ALL)
STUDY E1910
Phase III
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABLnegative B lineage Acute Lymphoblastic Leukemia in Adults

Acute Myeloid Leukemia (AML)
STUDY 2017-006
Phase I/II
A Phase 1b/2 Study of Entospletinib (GS-9973) Monotherapy and in Combination with Chemotherapy in Patients with Acute Myeloid Leukemia (AML)

STUDY NEW BMTCTN1506
Phase III
A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients with FLT3/ITD AML.

STUDY NEW S1612
Phase II/III
A Randomized Phase II/III Trial Of Novel Therapeutics Versus Azacitidine In Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (Mds), Age 60 Or Older

STUDY 2016-035
Phase I
A Phase 1/1b, Multicenter, Open-label, Dose-Escalation Study of FT-2102 as a Single Agent and in Combination with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome with an IDH1 Mutation

STUDY 2016-103
Phase I
An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia

Chronic Myeloid Leukemia (CML)
STUDY 2015-128
Phase II
A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

LYMPHOMA
Hodgkin’s
STUDY 2016-033
Phase II
A Phase II Multicenter Single Arm Study to Evaluate the Efficacy and Safety of Single Agent Bruton's Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with Relapsed Refractory Hodgkin's Lymphoma

STUDY 2017-132
<table>
<thead>
<tr>
<th>Phase II</th>
<th>An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults with Newly Diagnosed Classical Hodgkin Lymphoma with Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2017-100</td>
<td>Phase III</td>
</tr>
<tr>
<td>STUDY NEW 2018-013</td>
<td>Phase I/II</td>
</tr>
<tr>
<td>STUDY 2016-058</td>
<td>Phase III</td>
</tr>
<tr>
<td><strong>Non-Hodgkin's</strong></td>
<td><strong>Aggressive (Mantle Cell, Large B-Cell Lymphoma)</strong></td>
</tr>
<tr>
<td>STUDY 2013-178</td>
<td>Phase I/II</td>
</tr>
<tr>
<td>STUDY 2017-007</td>
<td>Phase I</td>
</tr>
<tr>
<td>STUDY 2013-047</td>
<td>Phase I</td>
</tr>
<tr>
<td>STUDY 2017-125</td>
<td>Phase III</td>
</tr>
<tr>
<td>STUDY 2016-147</td>
<td>Phase II</td>
</tr>
<tr>
<td>STUDY 2015-150</td>
<td>Phase I/II</td>
</tr>
<tr>
<td>Study</td>
<td>Year</td>
</tr>
<tr>
<td>-------</td>
<td>------</td>
</tr>
<tr>
<td>Indolent STUDY 2017-068</td>
<td>Phase II</td>
</tr>
<tr>
<td>T cell STUDY 2009-139</td>
<td>Phase I</td>
</tr>
<tr>
<td>STUDY 2016-139</td>
<td>Phase I</td>
</tr>
<tr>
<td>STUDY 2016-210</td>
<td>Phase I/II</td>
</tr>
<tr>
<td>STUDY NEW 2016-056</td>
<td>Phase II</td>
</tr>
<tr>
<td>STUDY NEW 2018-003</td>
<td>Phase I</td>
</tr>
<tr>
<td>STUDY 2017-069</td>
<td>Phase I/II</td>
</tr>
<tr>
<td>STUDY 2017-008</td>
<td>Phase I</td>
</tr>
<tr>
<td>MYELODYSPLASTIC SYNDROME (MDS) STUDY 2014-037</td>
<td>Phase I</td>
</tr>
<tr>
<td>STUDY 2016-035</td>
<td>Phase I</td>
</tr>
<tr>
<td>MYELOPROLIFERATIVE DISORDERS STUDY 2017-079</td>
<td>Phase II</td>
</tr>
</tbody>
</table>
STUDY NEW S1612
Phase II/III
A Randomized Phase II/III Trial Of Novel Therapeutics Versus Azacitidine In Newly Diagnosed Patients With Acute Myeloid Leukemia (AML) Or High-Risk Myelodysplastic Syndrome (Mds), Age 60 Or Older

STUDY 2017-133
Phase I
A Phase Ib Study of Ruxolitinib in Combination with PUH71 for the Treatment of Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post-PV MF), and Post-Essential Thrombocythemia MF (post-ET MF)

OTHER
STUDY 2013-113
Phase II
A Multicenter Phase 2 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 (ibrutinib) for Treatment of Relapsed Hairy Cell Leukemia

STUDY 2016-148
Phase I/II
A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects with Hematological Malignancies

STUDY EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)

RETURN TO TOP

Immunotherapy Clinical Trials

There are currently no open clinical trials. For more information on Karmanos Clinical Trials please contact the Karmanos Clinical Trials Office at 313-576-9790.

RETURN TO TOP

Melanoma/Skin Clinical Trials

For more information on Melanoma/Skin Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

ADVANCED
STUDY 2015-034
Phase I/II
A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

STUDY 2016-210
Phase I/II
An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas

STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of
BI 754091 In Patients With Advanced Solid Tumors

**STUDY 2017-087**

**Phase I**

A Phase 1, Open-label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies

**STUDY 2017-064**

**Phase I/II**

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

**STUDY 2017-112**

**Phase I/II**

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

**STUDY 2017-127**

**Phase I**

A Phase IB Study Evaluating Cobimetinib Plus Atezolizumab in Patients with Advanced BRAFV600 Wild-Type Melanoma Who Have Progressed During or After Treatment with Anti-PD-1 Therapy and Atezolizumab Monotherapy in Patients with Previously Untreated Advanced BRAFV600 Wild-Type Melanoma

**STUDY 2017-069**

**Phase I/II**

A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

**STUDY 2016-037**

**Phase I**

A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors

**STUDY EA6134**

**Phase III**

A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma

**STUDY 2015-004**

**Phase II**

A Multi-Center Phase 2 Open Label Study to Evaluate Safety and Efficacy in Subjects with Melanoma Metastatic to the Brain treated with Nivolumab in Combination with Ipilimumab followed by Nivolumab Monotherapy

**STUDY 2013-047**

**Phase I**

A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas

**STUDY 2009-139**

**Phase I**

Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

**STUDY S1320**

**Phase II**

A Randomized, Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAFV600E/K Mutant Melanoma

**STUDY 2016-017**

**Phase I/II**

A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab* (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies
OTHER

STUDY 2015-156
Phase I
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

STUDY 2017-064
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumors

STUDY 2016-149
Phase I/II
A Phase 1b/2, Open-label, Multicenter, Dose-escalation and Expansion Trial of Intratumoral SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

STUDY 2016-055
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

STUDY EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)

RETURN TO TOP

Neuro-Oncology Clinical Trials

There are currently no open clinical trials. For more information on Karmanos Clinical Trials please contact the Karmanos Clinical Trials Office at 313-576-9790.

RETURN TO TOP

Phase I Clinical Trials

For more information on Phase 1 Clinical Trials or to refer a patient, please call 313-576-9204 or email Phase1NewPt@karmanos.org. All patients will need to go through an initial new patient screening consultation to determine if they are eligible for one of our Phase 1 studies and to ensure that it is the best treatment option available for them.

ALL SOLID TUMORS

STUDY 2011-166
Phase I
A Phase 1 and Pharmacokinetic Single Agent Study of Romidepsin in Patients with Lymphomas, Chronic Lymphocytic Leukemia and Select Solid Tumors and Varying Degrees of Liver Dysfunction

STUDY 2015-005
Phase I
A Phase 1A Dose-Escalation Study of OBP-801 in Patients with Advanced Solid Tumors.
<table>
<thead>
<tr>
<th>Study Number</th>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2016-050</td>
<td>Phase I</td>
<td>A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, an Anti-Glypican 3 (GPC3)/CD3 Bispecific Antibody, in Patients with Advanced Solid Tumors.</td>
</tr>
<tr>
<td>STUDY 2017-111</td>
<td>Phase I</td>
<td>A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2017-122</td>
<td>Phase I</td>
<td>A Phase 1 Trial of MK-4280 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2017-097</td>
<td>Phase I</td>
<td>An Open-Label, Single Sequence, Crossover Drug-Drug Interaction Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of CYP3A4 and CYP2C9 Substrates in Patients</td>
</tr>
<tr>
<td>STUDY 2017-086</td>
<td>Phase I/II</td>
<td>A Phase 1-2, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2016-170</td>
<td>Phase I/II</td>
<td>A Phase I/IIa, Open-Label, Dose-escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Liposomal Vinorelbine Tartrate Injection in Patients with Advanced Malignancy</td>
</tr>
<tr>
<td>STUDY 2016-189</td>
<td>Phase I</td>
<td>A Phase 1, Multicenter, Open-Label, Dose-Escalation Study of SGN-2FF in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2017-087</td>
<td>Phase I</td>
<td>A Phase 1, Open-label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies</td>
</tr>
<tr>
<td>STUDY 2016-210</td>
<td>Phase I/II</td>
<td>An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas</td>
</tr>
<tr>
<td>STUDY 2016-185</td>
<td>Phase I/II</td>
<td>A Phase 1b/2 Trial of Hu5F9-G4 in Combination with Cetuximab in Patients with Solid Tumors and Advanced Colorectal Cancer</td>
</tr>
<tr>
<td>STUDY 2017-036</td>
<td>Phase I</td>
<td>A Phase I Open-Label Pharmacokinetics and Safety Study of Talazoparib (MDV3800) in Patients With Advanced Solid Tumors and Normal or Varying Degrees of Renal Impairment</td>
</tr>
<tr>
<td>STUDY 2017-037</td>
<td>Phase II</td>
<td>A Single-Arm, Open-Label, Multicenter, Extended Treatment, Safety Study in Patients Treated With Talazoparib</td>
</tr>
<tr>
<td>STUDY 2017-088</td>
<td>Phase I</td>
<td>A Phase 1 Trial of MK-7684 as Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY</td>
<td>Phase</td>
<td>Study Description</td>
</tr>
<tr>
<td>---------------------</td>
<td>--------</td>
<td>------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>STUDY 2016-152</td>
<td>Phase I</td>
<td>A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2016-135</td>
<td>Phase I/II</td>
<td>A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2017-052</td>
<td>Phase I/II</td>
<td>A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an anti-PD-1 Monoclonal Antibody, in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2016-157</td>
<td>Phase I</td>
<td>Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2015-056</td>
<td>Phase I</td>
<td>A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2015-011</td>
<td>Phase I</td>
<td>A Phase 1b Study to Assess Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PLX9486 as a Single Agent and in Combination with PLX3397 in Patients with Advanced Solid Tumors and Patients with Locally Advanced, Unresectable, or Metastatic Gastrointestinal Stromal Tumor (GIST) Who Have Been Previously Treated with Imatinib Mesylate, Sunitinib Malate, and Regorafenib</td>
</tr>
<tr>
<td>STUDY 2015-034</td>
<td>Phase I/II</td>
<td>A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2016-042</td>
<td>Phase I</td>
<td>A Phase I, Open-Label Study to Determine the Effect of Repeat Dosing of Trametinib on the Pharmacokinetics of a Combined Oral Contraceptive (Norethindrone plus Ethinyl Estradiol) in Female Patients with Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2016-037</td>
<td>Phase I</td>
<td>A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2009-139</td>
<td>Phase I</td>
<td>Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer</td>
</tr>
<tr>
<td>STUDY 2011-082</td>
<td>Phase I</td>
<td>An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors (NCI# 8808, UPCI# 10-115)</td>
</tr>
<tr>
<td>STUDY 2016-075</td>
<td>Phase I/II</td>
<td>A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Clear Cell Renal Cell Carcinoma and Other Solid Tumors</td>
</tr>
<tr>
<td>STUDY</td>
<td>Title</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-------</td>
<td></td>
</tr>
<tr>
<td><strong>TUMOR SPECIFIC</strong>&lt;br&gt;STUDY 2016-210&lt;br&gt;Phase I/II&lt;br&gt;An Open-Label, Dose-Finding And Proof Of Concept Study Of The PD-L1 Probody Therapeutic, CX-072, As Monotherapy And In Combination With Yervoy (Ipilimumab) Or With Zelboraf (Vemurafenib) In Subjects With Advanced Or Recurrent Solid Tumors Or Lymphomas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>**STUDY 2016-079&lt;br&gt;Phase I&lt;br&gt;An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>**STUDY 2017-097&lt;br&gt;Phase I&lt;br&gt;An Open-Label, Single Sequence, Crossover Drug-Drug Interaction Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of CYP3A4 and CYP2C9 Substrates in Patients</td>
<td></td>
<td></td>
</tr>
<tr>
<td>**STUDY 2016-037&lt;br&gt;Phase I&lt;br&gt;A Phase 1 Study of ALKS 4230 in Subjects with Advanced Solid Tumors</td>
<td></td>
<td></td>
</tr>
<tr>
<td>**STUDY 2017-112&lt;br&gt;Phase I/II&lt;br&gt;A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>**STUDY 2015-137&lt;br&gt;Phase I&lt;br&gt;A Phase 1b, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Trastuzumab Emtansine or with Trastuzumab and Pertuzumab (with and without Docetaxel) in Patients with HER2-Positive Breast Cancer and Atezolizumab with Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>**STUDY 2017-037&lt;br&gt;Phase II&lt;br&gt;A Single-Arm, Open-Label, Multicenter, Extended Treatment, Safety Study in Patients Treated With Talazoparib</td>
<td></td>
<td></td>
</tr>
<tr>
<td>**STUDY 2015-046&lt;br&gt;Phase I&lt;br&gt;A Phase I, Multicenter, Open-Label, Two-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women with Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td>**STUDY 2013-047&lt;br&gt;Phase I&lt;br&gt;A Phase 1 Multiple Ascending Dose Study of DS-3032B, an Oral MDM2 Inhibitor, in Subjects with Advanced Solid Tumors or Lymphomas</td>
<td></td>
<td></td>
</tr>
<tr>
<td>**STUDY 2017-029&lt;br&gt;Phase I&lt;br&gt;An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>**STUDY 2017-075&lt;br&gt;Phase I&lt;br&gt;A Phase 1, First-in-Man, Multicenter, Open-Label, Dose-Escalation Study of Single-Agent GBR 1302 in Subjects with HER2 Positive Cancers</td>
<td></td>
<td></td>
</tr>
<tr>
<td>**STUDY 2017-018&lt;br&gt;Phase I&lt;br&gt;A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women with Hormone Receptor Positive Breast Cancer</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>STUDY 2017-064</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2015-034
Phase I/II
A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

STUDY 2016-152
Phase I
A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors

STUDY 2017-085
Phase I
A Phase 1a/1b Dose Escalation and Expansion Study of Single-Agent SC-003 in Subjects with Platinum-Resistant/Refractory Ovarian Cancer

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Ipilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2016-055
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

GENOMIC TESTING SPECIFIC
STUDY 2016-050
Phase I
A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, an Anti-Glypican 3 (GPC3)/CD3 Bispecific Antibody, in Patients with Advanced Solid Tumors.

STUDY 2017-097
Phase I
An Open-Label, Single Sequence, Crossover Drug-Drug Interaction Study Assessing the Effect of Pexidartinib on the Pharmacokinetics of CYP3A4 and CYP2C9 Substrates in Patients

STUDY 2016-157
Phase I
Phase I Clinical Trial of VX-970 in Combination with the Topoisomerase I Inhibitor Irinotecan in Patients with Advanced Solid Tumors

STUDY 2015-137
Phase I
A Phase 1b, Open-Label Study Evaluating the Safety and Pharmacokinetics of Atezolizumab (Anti-PD-L1 Antibody) in Combination with Trastuzumab Emtansine or with Trastuzumab and Pertuzumab (with and without Docetaxel) in Patients with HER2-Positive Breast Cancer and Atezolizumab with Doxorubicin and Cyclophosphamide in HER2-Negative Breast Cancer

Sarcoma Clinical Trials
There are currently no open clinical trials. For more information on Karmanos Clinical Trials please contact the Karmanos Clinical Trials Office at 313-576-9790.
Thoracic Clinical Trials

For more information on Thoracic Clinical Trials, contact the Karmanos Clinical Trials Office at 313-576-9790. To refer a patient for these clinical trials, contact the Karmanos Patient Concierge at 800-527-6266, email newpt@karmanos.org or fill out this online referral form.

ADJUVANT
STUDY 2015-080
Phase III
A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (ANTI-PD-L1 ANTIBODY) Compared with Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in PD-L1-Selected Patients with Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer

STAGE I/II
STUDY 2016-110
Phase II
A Phase II, Open-label, Multicenter, Single-arm Study To Investigate The Efficacy And Safety Of Atezolizumab As Neoadjuvant And Adjuvant Therapy In Patients With Stage IB, II, Or IIIA Resectable And Untreated Non-Small Cell Lung Cancer

STUDY A081105
Phase III
Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

STAGE III A/B
STUDY 2016-110
Phase II
A Phase II, Open-label, Multicenter, Single-arm Study To Investigate The Efficacy And Safety Of Atezolizumab As Neoadjuvant And Adjuvant Therapy In Patients With Stage IB, II, Or IIIA Resectable And Untreated Non-Small Cell Lung Cancer

STUDY S1400
Phase II/III
A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)

STAGE IV
ALK
STUDY 2009-139
Phase I
Phase I Safety, Pharmacokinetic and Pharmcodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

STUDY 2017-116
NA
An Expanded Access Protocol for Lorlatinib for Treatment of Patients with Advanced Non Small Cell Lung Cancer Harboring Specific Molecular Alterations

EGFR
STUDY 2016-161
Phase I/II
An Open-Label Phase 1/2 Study of INCB039110 in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
<table>
<thead>
<tr>
<th>Study Code</th>
<th>Phase</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>STUDY 2017-145</td>
<td>Phase II</td>
<td>A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)</td>
</tr>
<tr>
<td>STUDY 2015-133</td>
<td>Phase II</td>
<td>A Phase II, Multicenter, Study of Oral cMET Inhibitor INC280 in Adult Patients with EGFR Wild-type (wt), Advanced Nonsmall Cell Lung Cancer (NSCLC)</td>
</tr>
<tr>
<td>Other Genetic Marker</td>
<td>STUDY S1400</td>
<td>A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-MAP)</td>
</tr>
<tr>
<td>STUDY 2017-093</td>
<td>Phase II</td>
<td>A Phase 2 Study of MEDI4736 (durvalumab) and Tremelimumab Alone or in Combination with High or Low-Dose Radiation in Metastatic Colorectal and NSCLC</td>
</tr>
<tr>
<td>STUDY 2017-145</td>
<td>Phase II</td>
<td>A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)</td>
</tr>
<tr>
<td>STUDY 2017-111</td>
<td>Phase I</td>
<td>A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors</td>
</tr>
<tr>
<td>STUDY 2016-203</td>
<td>Phase III</td>
<td>A Phase 3, Prospective, Randomized, Double-Blind, Multi-Center, Study of the Efficacy and Safety of Lanreotide Autogel/Depot 120 MG Plus BSC vs. Placebo Plus BSC for Tumor Control in Subjects with Well Differentiated, Metastatic and/or Unresectable Typical or Atypical Lung Neuroendocrine Tumors</td>
</tr>
<tr>
<td>STUDY 2016-034</td>
<td>Phase I</td>
<td>A Phase 1b Study of Abemaciclib in Combination with Pembrolizumab for Patients with Stage IV Non-Small Cell Lung Cancer or Hormone Receptor Positive, HER2 Negative Breast Cancer</td>
</tr>
<tr>
<td>STUDY 2016-134</td>
<td>Phase II</td>
<td>A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Subjects with Advanced Non-small Cell Lung Cancer (FRACTION-Lung)</td>
</tr>
<tr>
<td>STUDY 2016-017</td>
<td>Phase I/II</td>
<td>A Phase 1B/2 Open-Label Study to Evaluate Safety, Clinical Activity, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination with Other Cancer Immunotherapies in Patients with Advanced Malignancies</td>
</tr>
<tr>
<td>STUDY 2016-091</td>
<td>Phase I</td>
<td>An Open-Label, Phase 1 Study of the Safety and Immunogenicity of JNJ-64041757, a Live Attenuated Listeria monocytogenes Immunotherapy, in Subjects With Non-Small Cell Lung Cancer</td>
</tr>
<tr>
<td>STUDY 2009-139</td>
<td>Phase I</td>
<td>Phase I Safety, Pharmacokinetic and Pharmcodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer</td>
</tr>
</tbody>
</table>
STUDY 2016-055
Phase I
A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers

RECURRENT
ALK
STUDY 2009-139
Phase I
Phase I Safety, Pharmacokinetic and Pharmcodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

STUDY 2017-106
Phase II
Phase II Multi-Center Study of Pembrolizumab in Combination with Platinumbased Doublet Chemotherapy in Patients with EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) with Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)

EGFR
STUDY 2017-106
Phase II
Phase II Multi-Center Study of Pembrolizumab in Combination with Platinumbased Doublet Chemotherapy in Patients with EGFR Mutation and ALK Positive NSCLC (Non-Small Cell Lung Cancer) with Progressive Disease Following Prior Tyrosine Kinase Inhibitors (TKIs)

Other Genetic Marker
STUDY 2009-139
Phase I
Phase I Safety, Pharmacokinetic and Pharmcodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

SCLC EXTENSIVE
STUDY 2017-064
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2017-138
Phase I/II
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-Argl-PEG) in Combination with Pembrolizumab in the Treatment of Patients with Extensive Disease (ED) Small Cell Lung Cancer (SCLC)

MESOTHELIOMA
STUDY 2017-064
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2017-112
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies
SARCOMA
STUDY 2009-139
Phase I
Phase I Safety, Pharmacokinetic and Pharmcodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

OTHER
STUDY 2009-139
Phase I
Phase I Safety, Pharmacokinetic and Pharmcodynamic Study of PF-02341066, A C-Met/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer

STUDY EAY131
Phase II
Molecular Analysis for Therapy Choice (MATCH)

STUDY 2017-112
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01949 in Combination with Immune Therapies in Subjects with Advanced or Metastatic Malignancies

STUDY 2016-189
Phase I
A Phase 1, Multicenter, Open-Label, Dose-Escalation Study of SGN-2FF in Patients with Advanced Solid Tumors

STUDY 2016-116
Phase II
A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors

STUDY 2017-087
Phase I
A Phase 1, Open-label, Dose-Escalation Study of SEA-CD40 in Adult Patients with Advanced Malignancies

STUDY 2016-152
Phase I
A Phase 1b Study to Evaluate TAK-659 in Combination With Nivolumab in Patients With Advanced Solid Tumors

STUDY 2017-064
Phase I/II
A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

STUDY 2017-069
Phase I/II
A Phase 1/2a Study of BMS-986205 Administered in Combination with Nivolumab anti-PD-1 Monoclonal Antibody) and in Combination with Both Nivolumab and Iplilimumab (anti-CTLA-4 Monoclonal Antibody) in Advanced Malignant Tumors

STUDY 2017-029
Phase I
An Open-Label, Phase I Trial To Determine The Maximum-Tolerated Dose And Investigate Safety, Pharmacokinetics, And Efficacy Of BI 754091 In Patients With Advanced Solid Tumours

STUDY 2015-156
Phase I
A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors
To refer a patient or for more information on open clinical trials at the Karmanos Cancer Institute, call 1-800-KARMANOS (1-800-527-6266)

To schedule an appointment, please call between 7:30 AM â€“ 5:30 PM, Monday â€“ Friday.